Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
Status:
Recruiting
Trial end date:
2023-11-03
Target enrollment:
Participant gender:
Summary
This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group
study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal
female participants with moderate or severe hepatic impairment compared with post-menopausal
female participants with normal hepatic function.
Participants will be enrolled within the following groups based on their CP classification
score as determined at screening:
- Group 1: Matched-control healthy participants with normal hepatic function.
- Group 2: Participants with moderate hepatic impairment (CP Class B, score of 7 to 9).
- Group 3: Participants with severe hepatic impairment (CP Class C, score of 10 to 15).